KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Long-Term Debt Repayments (2017 - 2024)

Pacific Biosciences Of California has reported Long-Term Debt Repayments over the past 5 years, most recently at $152000.0 for Q2 2024.

  • Quarterly results put Long-Term Debt Repayments at $152000.0 for Q2 2024, down 67.31% from a year ago — trailing twelve months through Mar 2025 was $152000.0 (down 91.23% YoY), and the annual figure for FY2024 was $490000.0, down 73.4%.
  • Long-Term Debt Repayments for Q2 2024 was $152000.0 at Pacific Biosciences Of California, down from $338000.0 in the prior quarter.
  • Over the last five years, Long-Term Debt Repayments for PACB hit a ceiling of $16.0 million in Q1 2020 and a floor of $152000.0 in Q2 2024.
  • Median Long-Term Debt Repayments over the past 4 years was $428000.0 (2022), compared with a mean of $1.8 million.
  • Biggest five-year swings in Long-Term Debt Repayments: rose 18.54% in 2023 and later crashed 67.31% in 2024.
  • Pacific Biosciences Of California's Long-Term Debt Repayments stood at $16.0 million in 2020, then plummeted by 97.32% to $428000.0 in 2022, then grew by 3.97% to $445000.0 in 2023, then crashed by 65.84% to $152000.0 in 2024.
  • The last three reported values for Long-Term Debt Repayments were $152000.0 (Q2 2024), $338000.0 (Q1 2024), and $445000.0 (Q4 2023) per Business Quant data.